• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实性型肺腺癌中 VEGF-A 的增加降低了患者的生存率。

Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients' survival.

机构信息

Department of Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Gyeonggi-do, 11923, Republic of Korea.

出版信息

Sci Rep. 2021 Jan 14;11(1):1321. doi: 10.1038/s41598-020-79907-6.

DOI:10.1038/s41598-020-79907-6
PMID:33446784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7809025/
Abstract

The histological classification of lung adenocarcinoma includes 5 types: lepidic, acinar, papillary, micropapillary and solid. The complex gene interactions and anticancer immune response of these types are not well known. The aim of this study was to reveal the survival rates, genetic alterations and immune activities of the five histological types and provide treatment strategies. This study reviewed the histological findings of 517 patients with lung adenocarcinoma from The Cancer Genome Atlas (TCGA) database and classified them into five types. We performed gene set enrichment analysis (GSEA) and survival analysis according to the different types. We found six oncogenic gene sets that were higher in lung adenocarcinoma than in normal tissues. In the survival analysis of each type, the acinar type had a favorable prognosis, and the solid subtype had an unfavorable prognosis; however, the survival differences between the other types were not significant. Our study focused on the solid type, which had the poorest prognosis. The solid type was related to adaptive immune resistance associated with elevated CD8 T cells and high CD274 (encoding PD-L1) expression. In the pathway analyses, the solid type was significantly related to high vascular endothelial growth factor (VEGF)-A expression, reflecting tumor angiogenesis. Non-necrosis/low immune response affected by high VEGF-A was associated with worse prognosis. The solid type associated with high VEGF-A expression may contribute to the development of therapeutic strategies for lung adenocarcinoma.

摘要

肺腺癌的组织学分类包括 5 种类型:贴壁型、腺泡型、乳头状、微乳头型和实体型。这些类型的复杂基因相互作用和抗癌免疫反应尚不清楚。本研究旨在揭示五种组织学类型的生存率、遗传改变和免疫活性,并提供治疗策略。本研究回顾了来自癌症基因组图谱(TCGA)数据库的 517 例肺腺癌患者的组织学发现,并将其分为 5 种类型。我们根据不同类型进行了基因集富集分析(GSEA)和生存分析。我们发现了六个在肺腺癌中高于正常组织的致癌基因集。在每种类型的生存分析中,腺泡型预后良好,实体型预后不良;然而,其他类型之间的生存差异不显著。我们的研究集中在预后最差的实体型上。实体型与适应性免疫抵抗有关,与 CD8 T 细胞升高和 CD274(编码 PD-L1)表达升高有关。在通路分析中,实体型与高血管内皮生长因子(VEGF)-A 表达显著相关,反映了肿瘤血管生成。非坏死/高免疫反应受高 VEGF-A 影响与预后较差相关。与高 VEGF-A 表达相关的实体型可能有助于制定肺腺癌的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/0aae78508fc8/41598_2020_79907_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/daad30a58ce2/41598_2020_79907_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/25eba3a912fd/41598_2020_79907_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/a75dcf94584a/41598_2020_79907_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/505e38f31cb0/41598_2020_79907_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/0aae78508fc8/41598_2020_79907_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/daad30a58ce2/41598_2020_79907_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/25eba3a912fd/41598_2020_79907_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/a75dcf94584a/41598_2020_79907_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/505e38f31cb0/41598_2020_79907_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/554f/7809025/0aae78508fc8/41598_2020_79907_Fig5_HTML.jpg

相似文献

1
Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients' survival.实性型肺腺癌中 VEGF-A 的增加降低了患者的生存率。
Sci Rep. 2021 Jan 14;11(1):1321. doi: 10.1038/s41598-020-79907-6.
2
Cancer-associated fibroblasts are associated with poor prognosis in solid type of lung adenocarcinoma in a machine learning analysis.在机器学习分析中,癌症相关成纤维细胞与实体型肺腺癌不良预后相关。
Sci Rep. 2021 Aug 18;11(1):16779. doi: 10.1038/s41598-021-96344-1.
3
Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.肺的腺泡或乳头为主型腺癌的预后因素。
Lung Cancer. 2019 Nov;137:129-135. doi: 10.1016/j.lungcan.2019.09.026. Epub 2019 Sep 30.
4
Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.桥粒斑蛋白-2 通过激活肺腺癌中的 EGFR 信号通路加速细胞增殖和迁移。
Pathol Res Pract. 2019 Jul;215(7):152438. doi: 10.1016/j.prp.2019.152438. Epub 2019 May 13.
5
Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.碱性成纤维细胞生长因子(bFGF)和血管内皮生长因子(VEGF)水平,作为非小细胞肺癌的预后指标。
Eur J Cardiothorac Surg. 2004 Mar;25(3):443-8. doi: 10.1016/j.ejcts.2003.11.031.
6
Loss of miR-145-5p Causes Ceruloplasmin Interference with PHD-Iron Axis and HIF-2α Stabilization in Lung Adenocarcinoma-Mediated Angiogenesis.miR-145-5p 的缺失导致铜蓝蛋白干扰 PHD-铁轴和 HIF-2α 稳定在肺腺癌介导的血管生成中。
Int J Mol Sci. 2020 Jul 18;21(14):5081. doi: 10.3390/ijms21145081.
7
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.实性为主型肺腺癌的遗传和免疫特征揭示了潜在的免疫治疗策略。
J Thorac Oncol. 2018 Jan;13(1):85-96. doi: 10.1016/j.jtho.2017.10.020. Epub 2017 Nov 7.
8
Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.切除的ⅠB 期肺腺癌中实性或微乳头状模式的预后意义和辅助化疗生存获益。
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1227-1235.e2. doi: 10.1016/j.jtcvs.2017.09.143. Epub 2017 Nov 7.
9
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma.肺腺癌各亚型间独特的血管生成 miRNA-mRNA 表达谱。
Pathol Oncol Res. 2020 Apr;26(2):1089-1096. doi: 10.1007/s12253-019-00664-7. Epub 2019 May 2.
10
LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression.LINC00173.v1 通过海绵吸附 miR-511-5p 调控 VEGFA 表达促进肺鳞癌血管生成和进展。
Mol Cancer. 2020 May 30;19(1):98. doi: 10.1186/s12943-020-01217-2.

引用本文的文献

1
Bispecific antibody for lung cancer: mechanisms and clinical insights.用于肺癌的双特异性抗体:作用机制与临床见解
Front Immunol. 2025 May 29;16:1572802. doi: 10.3389/fimmu.2025.1572802. eCollection 2025.
2
Neuronal guanine nucleotide exchange factor promotes the axonal growth and cancer cell proliferation via Ephrin-A3/EphA2 axis in lung adenocarcinoma.神经元鸟嘌呤核苷酸交换因子通过Ephrin-A3/EphA2轴促进肺腺癌中的轴突生长和癌细胞增殖。
J Transl Med. 2025 Feb 28;23(1):246. doi: 10.1186/s12967-025-06233-8.
3
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.

本文引用的文献

1
HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.HER4 通过促进上皮-间充质转化促进结直肠癌的进展。
Mol Med Rep. 2020 Apr;21(4):1779-1788. doi: 10.3892/mmr.2020.10974. Epub 2020 Feb 4.
2
Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.抗 PD-1 治疗后主要组织相容性复合体 I 类表达丢失的转移性黑色素瘤病变中肿瘤浸润淋巴细胞的肿瘤反应性分析。
J Invest Dermatol. 2019 Jul;139(7):1490-1496. doi: 10.1016/j.jid.2019.01.007. Epub 2019 Jan 23.
3
SCT510 生物类似药与贝伐珠单抗用于晚期非鳞状非小细胞肺癌一线治疗的疗效和安全性:一项随机、双盲、III 期研究。
Adv Ther. 2024 Nov;41(11):4032-4048. doi: 10.1007/s12325-024-02965-z. Epub 2024 Sep 4.
4
Ornidazole Inhibits the Angiogenesis and Migration Abilities of Non-small Cell Lung Cancer (NSCLC) via Downregulation of VEGFA/VEGFR2/NRP-1 and PI3K/AKT/mTOR Pathways.奥硝唑通过下调 VEGFA/VEGFR2/NRP-1 和 PI3K/AKT/mTOR 通路抑制非小细胞肺癌(NSCLC)的血管生成和迁移能力。
Cell Biochem Biophys. 2024 Dec;82(4):3277-3285. doi: 10.1007/s12013-024-01358-x. Epub 2024 Jun 17.
5
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.雷莫西尤单抗联合多西他赛用于非小细胞肺癌患者化疗免疫治疗后的前瞻性观察研究
Oncologist. 2024 May 3;29(5):e681-e689. doi: 10.1093/oncolo/oyae001.
6
JAK2 Loss Arising From Tumor-Spread-Through-Air-Spaces (STAS) Promotes Tumor Progression by Suppressing CD8+ T Cells in Lung Adenocarcinoma: A Machine Learning Approach.肿瘤通过气腔播散(STAS)导致的JAK2缺失通过抑制肺腺癌中的CD8 + T细胞促进肿瘤进展:一种机器学习方法
J Korean Med Sci. 2024 Jan 15;39(2):e16. doi: 10.3346/jkms.2024.39.e16.
7
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.VEGF/VEGFR 靶向治疗与非小细胞肺癌的免疫治疗:靶向肿瘤微环境。
Int J Biol Sci. 2022 May 29;18(9):3845-3858. doi: 10.7150/ijbs.70958. eCollection 2022.
8
Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.非小细胞肺癌中VEGF和Ki67表达与淋巴结转移的相关性:一项系统评价和Meta分析
Evid Based Complement Alternat Med. 2022 Jun 28;2022:9693746. doi: 10.1155/2022/9693746. eCollection 2022.
9
Iloprost requires the Frizzled-9 receptor to prevent lung cancer.伊洛前列素需要卷曲蛋白9受体来预防肺癌。
iScience. 2022 May 23;25(6):104442. doi: 10.1016/j.isci.2022.104442. eCollection 2022 Jun 17.
10
Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma the Peroxisome Proliferator-Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway.宝藿苷I通过过氧化物酶体增殖物激活受体γ/血管内皮生长因子信号通路抑制多发性骨髓瘤中的肿瘤血管生成。
Front Pharmacol. 2022 Mar 7;13:822082. doi: 10.3389/fphar.2022.822082. eCollection 2022.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
VEGFb, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.VEGFb,VEGF-A 的剪接变异体,通过β1 整合素/VEGFR 自分泌环促进肺肿瘤的进展并逃避抗血管生成治疗。
Oncogene. 2019 Feb;38(7):1050-1066. doi: 10.1038/s41388-018-0486-7. Epub 2018 Sep 7.
5
Targeting VEGF/VEGFR to Modulate Antitumor Immunity.针对 VEGF/VEGFR 调节抗肿瘤免疫。
Front Immunol. 2018 May 3;9:978. doi: 10.3389/fimmu.2018.00978. eCollection 2018.
6
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.肺癌筛查,版本 3.2018,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. doi: 10.6004/jnccn.2018.0020.
7
The Immune Landscape of Cancer.癌症的免疫全景。
Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5.
8
Oncogenic Signaling Pathways in The Cancer Genome Atlas.癌症基因组图谱中的致癌信号通路。
Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.
9
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.人类癌症代谢表达亚型的分子特征及临床意义
Cell Rep. 2018 Apr 3;23(1):255-269.e4. doi: 10.1016/j.celrep.2018.03.077.
10
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.利用病理学图像上的深度学习技术研究肿瘤浸润淋巴细胞的空间组织和分子相关性。
Cell Rep. 2018 Apr 3;23(1):181-193.e7. doi: 10.1016/j.celrep.2018.03.086.